menu search

Relay therapeutics highlights interim data from bile duct cancer trial

Relay Therapeutics Inc (NASDAQ: RLAY) has announced an interim data Phase 1 trial of RLY-4008 in FGFR2-altered cholangiocarcinoma (bile duct cancer...

October 8, 2021, 12:24 pm

Ctx-009 (abl001/es104) clinical data presented today at the new drugs on the horizon plenary session of the 2021 aacr-nci-eortc international conference on molecular targets and cancer therapeutics

BOSTON & SEONGNAM, S. Korea & SHANGHAI/SUZHOU, China--(BUSINESS WIRE)-- #AACR--CTX-009 (ABL001/ES104) clinical data presented today at the New Drugs o...

October 8, 2021, 12:07 pm

Ctx-009 (abl001/es104) clinical data presented today at the new drugs on the horizon plenary session of the 2021 aacr-nci-eortc international conference on molecular targets and cancer therapeutics

BOSTON & SEONGNAM, S. Korea & SHANGHAI/SUZHOU, China--(BUSINESS WIRE)-- #AACR--CTX-009 (ABL001/ES104) clinical data presented today at the New Drugs o...

October 8, 2021, 12:07 pm

Ctx-009 (abl001/es104) clinical data presented today at the new drugs on the horizon plenary session of the 2021 aacr-nci-eortc international conference on molecular targets and cancer therapeutics

BOSTON & SEONGNAM, S. Korea & SHANGHAI/SUZHOU, China--(BUSINESS WIRE)-- #AACR--CTX-009 (ABL001/ES104) clinical data presented today at the New Drugs o...

October 8, 2021, 12:07 pm

Effector therapeutics stock gains on encouraging preclinical zotatifin data in breast cancer

eFFECTOR Therapeutics Inc (NASDAQ: EFTR), in collaboration with Baylor College of Medicine, announced the presentation of new positive data for zo...

October 8, 2021, 7:34 am

Effector therapeutics stock gains on encouraging preclinical zotatifin data in breast cancer

eFFECTOR Therapeutics Inc (NASDAQ: EFTR), in collaboration with Baylor College of Medicine, announced the presentation of new positive data for zo...

October 8, 2021, 7:34 am

Effector therapeutics stock gains on encouraging preclinical zotatifin data in breast cancer

eFFECTOR Therapeutics Inc (NASDAQ: EFTR), in collaboration with Baylor College of Medicine, announced the presentation of new positive data for zo...

October 8, 2021, 7:34 am

Evotec expands neuroscience collaboration with bristol myers squibb to include novel cell type

INCLUDES NEW CELL TYPES FOR STUDYING moleCULAR DISEASE SIGNATURES FOR DISCOVERY OF DISEASE-MODIFYING TH...

October 8, 2021, 1:50 am

Evotec expands neuroscience collaboration with bristol myers squibb to include novel cell type

INCLUDES NEW CELL TYPES FOR STUDYING moleCULAR DISEASE SIGNATURES FOR DISCOVERY OF DISEASE-MODIFYING TH...

October 8, 2021, 1:50 am

Evotec expands neuroscience collaboration with bristol myers squibb to include novel cell type

INCLUDES NEW CELL TYPES FOR STUDYING moleCULAR DISEASE SIGNATURES FOR DISCOVERY OF DISEASE-MODIFYING TH...

October 8, 2021, 1:50 am

Repare therapeutics issues statement regarding inadvertent issuance of phase 1/2 tresr rp-3500 clinical trial abstract by the aacr-nci-eortc virtual international conference

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage pr...

October 7, 2021, 5:08 pm

Repare therapeutics issues statement regarding inadvertent issuance of phase 1/2 tresr rp-3500 clinical trial abstract by the aacr-nci-eortc virtual international conference

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage pr...

October 7, 2021, 5:08 pm

Repare therapeutics issues statement regarding inadvertent issuance of phase 1/2 tresr rp-3500 clinical trial abstract by the aacr-nci-eortc virtual international conference

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage pr...

October 7, 2021, 5:08 pm

Lava therapeutics to present its bispecific gamma delta t cell engagers for treatment of cancer at the 2021 aacr-nci-eortc virtual international conference on molecular targets and cancer therapeutics

UTRECHT, The Netherlands and PHILADELPHIA, Oct. 07, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology com...

October 7, 2021, 11:31 am

Lava therapeutics to present its bispecific gamma delta t cell engagers for treatment of cancer at the 2021 aacr-nci-eortc virtual international conference on molecular targets and cancer therapeutics

UTRECHT, The Netherlands and PHILADELPHIA, Oct. 07, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology com...

October 7, 2021, 11:31 am

Lava therapeutics to present its bispecific gamma delta t cell engagers for treatment of cancer at the 2021 aacr-nci-eortc virtual international conference on molecular targets and cancer therapeutics

UTRECHT, The Netherlands and PHILADELPHIA, Oct. 07, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology com...

October 7, 2021, 11:31 am

Immunotherapeutic benefits of the dpx delivery platform featured in two poster presentations at the aacr-nci-eortc conference on molecular targets and cancer therapeutics

DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $IMV #DeliveryPlatform--IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceu...

October 7, 2021, 9:05 am

Immunotherapeutic benefits of the dpx delivery platform featured in two poster presentations at the aacr-nci-eortc conference on molecular targets and cancer therapeutics

DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $IMV #DeliveryPlatform--IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceu...

October 7, 2021, 9:05 am

Immunotherapeutic benefits of the dpx delivery platform featured in two poster presentations at the aacr-nci-eortc conference on molecular targets and cancer therapeutics

DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $IMV #DeliveryPlatform--IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceu...

October 7, 2021, 9:05 am

Recursion is granted fda fast track designation for rec-2282 for the potential treatment of nf2-mutated meningiomas

SALT LAKE CITY, Oct. 7, 2021 /PRNewswire/ -- Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology by integrating technol...

October 7, 2021, 7:55 am


Search within

Pages Search Results: